We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetic Remodeling Transforms E. Coli into Intestinal Pathogen

By LabMedica International staff writers
Posted on 09 Mar 2017
A team of molecular microbiologists has traced the genetic steps that enable the common bacteria Escherichia coli to transform from a commensal organism into a pathogenic one.

Enteropathogenic Escherichia coli (EPEC), the cause of severe intestinal infection, employ a type III secretion system (T3SS) to inject effector proteins into intestinal epithelial cells. More...
These effectors subvert host cell processes to promote bacterial colonization.

Investigators at the Hebrew University of Jerusalem showed that the T3SS also functioned to sense the host cell and to trigger in response posttranscriptional remodeling of gene expression in the bacteria. They further showed that upon effector injection, the effector-bound chaperone (CesT), which remained in the EPEC cytoplasm, antagonized the posttranscriptional regulator CsrA.

In obtaining these results, the investigators showed that after attaching to the host by means of pili, the bacteria sensed attachment to the human intestinal cells and activated gene expression in response. This was demonstrated by engineering one of these genes to express a protein that stained the expressing bacteria to appear green under the microscope. Under microscopic examination, the investigators observed that only the attached bacteria fluoresced in bright green, whereas non-attached bacteria remained dark.

"The next steps include mapping in detail the genes that change their expression upon attachment, and describing the precise effects of this expression remodeling,” said senior author Dr. Ilan Rosenshine, professor of bacteriology at the Hebrew University of Jerusalem. “Another important issue is testing whether similar regulation is involved in the infection processes of other pathogens."


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.